Trial
NCT03853317
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
ImmunityBio, Inc.
Collaborators
—
Condition
Merkel Cell Carcinoma
Intervention
Avelumab
Why stopped
Not meeting recruitment goal
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-09